 BioLineRx NASDAQ: BLRX has announced positive top-line results from GENESIS Phase 3 trial evaluating its lead clinical candidate, Motixafortide, combined with granulocyte colony-stimulating factor G-CSF, for hematopoietic stem-cell mobilization for autologous bone marrow transplantation in multiple myeloma patients. An analysis of data on all 122 enrolled patients found highly statistically significant evidence across all primary and secondary endpoints favoring Motixafortide in addition to G-CSF, as compared to placebo plus G-CSF. 